H.C. Wainwright assumed coverage of Genfit (GNFT) with a Buy rating and $9 price target The company is developing therapies for rare and severe liver diseases, with a focus on acute-on-chronic liver failure, the analyst tells investors in a research note. The firm says the company is expected to readout multiple meaningful clinical updates in 2025 and beyond, providing a number of catalysts for the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNFT: